On January 10, 2026, Swissmedic announced a dedicated platform for addressing specific questions related to Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP). This initiative provides clinical, quality, and regulatory teams an opportunity to engage with Swissmedic for detailed guidance on compliance matters relevant to their projects.
What changed?
Swissmedic has introduced a tailored consultation service aimed at resolving project-specific GMP and GDP questions. With the increased complexity of regulatory frameworks and the critical importance of compliance for global market access, this service offers timely guidance directly from Switzerland’s health authority.
Who is affected?
This initiative primarily benefits clinical, quality, and regulatory professionals involved in pharmaceutical and healthcare product development. Both companies operating in Switzerland and internationally can leverage this service to ensure regulatory alignment and adherence.
How to participate?
To participate, companies must engage Swissmedic via the official platform. The forum facilitates focused discussions on unique compliance challenges, ensuring clear solutions are provided. Visit Swissmedic’s official page for more details on how to schedule and prepare for a meeting.
FAQ
Q1. What topics can be discussed during these meetings?
A1. The consultations focus on GMP and GDP-related queries specific to an organization’s project or product.
Q2. Are these meetings open to international companies?
A2. Yes, Swissmedic welcomes queries from both domestic and international stakeholders.
Q3. How can teams prepare for these discussions?
A3. It is recommended to prepare detailed questions and any relevant supporting documents ahead of the scheduled consultation.
Conclusion
Swissmedic’s new initiative offers a direct and efficient way to address complex GMP and GDP issues. Clinical, quality, and regulatory teams are encouraged to take advantage of this forum to enhance compliance and streamline regulatory processes. For detailed participation guidelines, refer to Swissmedic’s website.
Disclaimer
This article is for informational purposes only. It does not constitute legal or regulatory advice. Please consult with qualified legal professionals or regulatory authorities for specific guidance.
Swissmedic Announcement
For full information about the Swissmedic announcement, see the link below.
https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/bewilligungen_zertifikate/authorisations/scientific-gmdp-fragestellungen.html